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Results: The	proportion	 of	 small‐for‐gestational‐age	was	11.8%	 following	 conven‐






Conclusions: We	 found	 an	 associated	 risk	 of	 children	 being	 born	 small‐for‐gesta‐
tional‐age	after	conventional	gonadotropin‐stimulated	in	vitro	fertilization	compared	
with	 natural	 cycle	 in	 vitro	 fertilization.	 This	 higher	 risk	 is	 significantly	 associated	
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1  | INTRODUC TION





existing	 diseases,	 duration	 of	 subfertility4	 and	 parental	 smoking);	
in	 vitro	 fertilization	 (IVF)	 laboratory	 procedures;5	 the	 number	 of	
oocytes	 retrieved;6	 and	 the	number	of	embryos	 transferred.	After	






















and	Reproductive	Medicine,	 Switzerland,	 from	2010	 to	 2016.	We	
retrieved	prospectively	 collected	data	and	prepared	 it	 for	analysis	
using	REDCap	electronic	data	(REDCap	8.5.19	Vaderbilt	University,	










unsuccessful	 NC‐IVF	 treatments.	 Women	 receiving	 those	 treat‐
























aspiration	 (FA)	 to	 delivery,	 plus	 14	 days.	We	used	 growths	 charts	
from	Voigt	&	Fenton14	to	determine	the	birthweight	percentile.	We	
defined	 a	 priori	 small‐for‐gestational‐age	 (SGA)	 as	 a	 birthweight	
gonadotropin	 to	 minimize	 the	 risk	 of	 small‐for‐gestational‐age	 and	 future	 health	
consequences.




Supraphysiological	 serum	 estradiol	 levels	 under	 gonado‐
tropin	 stimulation	 in	 in	 vitro	 fertilization	 are	 associated	
with	 a	 higher	 incidence	 of	 children	 born	 small‐for‐gesta‐
tional‐age.	We	propose	a	 reduction	 in	gonadotropin	dos‐
age	to	minimize	potential	negative	health	consequences.









follicular	 stimulation,	 depending	 on	 age,	 Anti‐Müllerian	 hormone	
level	and	antral	 follicle	count.	For	 the	antagonist	protocol,	we	use	
human	 menopausal	 gonadotropin	 (150‐300	 units	 a	 day)	 for	 fol‐
licular	 stimulation	 and	 0.25	 mg	 cetrorelix	 (gonadotropin‐releasing	
hormone	antagonist,	eg,	Cetrotide®)	once	a	day,	beginning	at	stimu‐
lation	day	6	or	7.	We	monitor	cycles	using	ultrasound,	check	serum	






hormone	 (LH)	 concentrations,	 once	 preovulatory.	 When	 the	 fol‐
licular	diameter	 reaches	 at	 least	16	mm	and	 the	E2	 concentration	




















We	 performed	 statistical	 analysis	 using	 Fisher's	 exact	 test	 (SGA	 and	







%/SD P valuen = 70 n = 85
Maternal	age	(y) 34.23 3.76 34.57 4.15 0.598a
Maternal	height	(cm) 166.99 6.04 167.01 7.98 0.982a
Maternal	weight	(kg) 62.18 10.57 62.28 11.17 0.956a
Maternal	BMI	(kg/m2) 22.32 3.76 22.33 3.72 0.982a
Parity	(nulliparous) 52 74.29 72 84.71 0.107b
Smoking	before	pregnancy	(y/n) 7 10 15 17.65 0.248c
Smoking	during	pregnancy	(y/n) 0 0 4 4.71 0.141c
Chronic	disease	mother	(y/n) 12 17.14 19 22.40 0.420b
AMH	mother 21.52 22.30 24.79 21.32 0.358a
Indication	for	IVF
Male	factor 45 64.30 42 49.41 0.381c
Endometriosis 11 15.70 18 21.18
Tube	factor 3 4.30 5 5.88
PCO‐S 0 0.00 3 3.53
Idiopathic 10 14.29 15 17.65







TA B L E  1  Patient	characteristics
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robust	standard	errors	controlling	for	clusters	in	the	regressions.	For	E2	
and	birth	percentile,	we	performed	multivariate	linear	regression,	and	for	














For	 statistical	 analysis,	 we	 used	 STATA	 statistical	 software	
Version	15	(Stata	Corporation,	College	Station,	Texas,	USA).





%/SD P valueN = 70 N = 85
Stimulation
Nb	previous	transfers	(n) 1.94 1.74 1.62 0.88 0.138a
Day	of	retrieval	(d) 12.65 1.87 12.19 2.09 0.207a
Nb	oocytes	retrieved	(n) 1.01 0.12 8.20 4.73 <0.001a
Nb	of	embryos	transferred	(n) 1.01 0.12 2.01 0.36 <0.001a
Day	of	embryo	transfer	(d) 2.69 0.71 2.61 0.74 0.531a
Total	gonadotropin	dosage	(IU) — — 2322.77 758.41 —
Estradiol	at	trigger	day	(pmol/L) 1028.94 330.39 10 459.78 4552.12 <0.001a
Estradiol	at	trigger	day	(>10	000	pmol/L) 0 0 40 48.19 <0.001b
Endometrium	thickness	(mm) 8.59 1.75 9.86 2.37 <0.001a
Pregnancy
Duration	of	pregnancy	(wk.d) 39.2 1.52 38.94 2.51 0.451a
Pregnancy	hypertension	(n) 1 1.43 1 1.18 0.890c
Pregnancy	complication	(n) 16 22.56 26 30.59 0.309b
Induction	of	labor	(n) 22 35.48 28 34.57 0.909b
Very	preterm	birth	(<31	wk) 0 0 2 2.35 0.418c
Preterm	birth	(31‐36	wk) 5 7.14 5 5.88
Term	birth	(≥37	wk) 65 92.85 78 91.76
Infant	gender	female 36 51.43 34 40 0.155b
Infant	gender	male 34 48.57 51 60
Birthweight	(g) 3310.34 475.08 3218.25 704.38 0.352a
VLBW	(<1500	g) 0 0 3 3.53 0.231b
LBW	(1500‐2500	g) 2 2.86 4 4.71
Birthweight	≥2500	g	(n) 68 65.9 78 91.76
Birthweight	≥4000	g	(n) 6 8.57 9 10.59 0.673b
Percentile	(mean) 43.14 26.74 38.58 27.91 0.304a
SGA	(≤5th	percentile) 2 2.86 10 11.76 0.039b
Birthweight	≤10th	percentile	(n) 10 14.49 18 21.18 0.285b
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2.6 | Ethics approval
The	 cantonal	 ethical	 committee	 of	 Bern	 (KEK	 Bern,	 397/15),	
Switzerland,	approved	the	study	on	26	January	2016.
3  | RESULTS














We	 found	 that	 stimulation	 characteristics	 were	 significantly	
higher	 in	 c‐IVF	but	 the	number	of	 previous	embryo	 transfers	was	
similar	(Table	2).
3.2 | Pregnancy characteristics
We	note	 that	 there	were	no	differences	 in	pregnancy	 complica‐
tions,	 eg,	 gestational	 hypertension,	 between	 the	 two	 groups	
(Table	2).	The	rate	of	preterm	births	(<37	gestational	weeks)	was	
8.24%	(n = 7)	 in	the	c‐IVF	group	and	7.14%	(n = 5)	 in	the	NC‐IVF	
(P = 1.000)	group.
The	 overall	 mean	 birthweight	 and	 percentile	 were	 3218	 g	
(±704	g),	38.6th	percentile	for	c‐IVF	and	3310	g	(±475),	43.1st	per‐
centile	for	NC‐IVF,	respectively,	P =	0.352.	The	proportion	of	LBW	
was	8.24%	(n = 7)	 in	c‐IVF	and	2.90%	(n = 2)	in	NC‐IVF,	P =	0.188,	
whereas	the	 incidence	of	birthweight	>4000	g	was	10.59%	(n = 9)	
in	the	c‐IVF	group	and	8.57%	(n	=	6)	in	the	NC‐IVF	group,	P = 0.673.
3.3 | Small‐for‐gestational‐age










The	 influence	 on	 birthweight	 percentile	 of	 an	 E2	 level	 of	





similar	odds	 ratios	 for	 stimulation	 schemes	 in	crude	and	adjusted	
analyses	(OR	1.45	vs	1.41,	1.48	and	1.41,	respectively).	 In	the	lin‐
ear	 regression,	 the	 association	 between	E2	 level	 and	 birthweight	
and	birthweight	percentile	is	modest.	Birthweights	and	birthweight	
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percentiles	are	lower	with	higher	E2	levels	on	ovulation	trigger	day.	
The	adjusted	linear	regression	of	NC‐IVF	children	shows	a	signifi‐












analysis.	We	did	 not	 have	 comparable	 information	 for	 the	 other	
four	 cases	 because	 the	 treating	 gynecologist	 did	 not	 perform	 a	
Doppler	measurement.
4  | DISCUSSION
This	 cohort	 study	 of	 singletons	 conceived	 after	 fresh	 IVF	 therapy	
focuses	 on	 the	 effect	 of	 ovarian	 stimulation	 on	 birth	 outcomes.	
Overall,	gonadotropins	seem	to	reduce	birthweight	and	birthweight	
TA B L E  3  Multilevel	logistic	regression	for	small‐for‐gestational‐age
N = 155
Unadjusted OR (95% 
CI) (for each determi‐













Stimulation	(c‐IVF) 4.53	(0.95‐21.61) 0.058 4.23	(0.87‐20.41) 0.073   1.05	(0.87‐1.17) 0.971
Mother	age	
(continuous)
1.01	(0.89‐1.17) 0.820 0.99	(0.88‐1.13) 0.952 1.01 
(0.87‐1.19)
0.811 1.01	(0.87‐1.17) 0.901
Mother	age	(>36	y) 0.98	(0.28‐3.48) 0.987       
Mother	height	
(continuous)





5.46	(1.42‐20.92) 0.013       
Mother	BMI	
(continuous)
0.99	(0.83‐1.18) 0.944 0.96	(0.78‐1.17) 0.668 0.96 
(0.74‐1.24)
0.753 0.98	(0.77‐1.24) 0.847
Mother	BMI	(<20	m2) 1.24	(0.35‐4.40) 0.735       





4.58	(1.35‐15.55) 0.015   3.83 
(1.06‐13.82)
0.041   
Nulliparous	(0	vs	≥1) 3.81a,b 0.188       
Smoking	during	preg‐
nancy	(y/n)
0.99	(0‐1.04)	b 0.984       
Vanishing	twin	(y/n) 2.25	(0.24‐20.73) 0.474       
Pregnancy	complica‐
tion	(y/n)
2.88	(0.87‐9.6) 0.083       
Pregnancy	hyperten‐
sion	(y/n)
12.90	(0.75‐222.94) 0.078       
Induction	of	labor	(y/n) 0.92	(0.26‐3.26) 0.902       
LBW	(<2500	vs	
≥2500	g)
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These	 results	 contribute	 to	 the	 important	 debate	 on	 whether	
ovarian	stimulation	poses	a	risk	for	SGA	or	LBW	and	to	the	health	
of	the	 IVF	children	 later	 in	 life	and	what	could	be	the	determining	
factors.
For	 children	 conceived	 by	 NC‐IVF,	 the	 incidence	 of	 SGA	 was	







Our	 results	 suggest	 that	 the	 stimulation	 is	detrimental	 if	 a	 su‐
praphysiological	 estradiol	 level	 is	 reached.	 Measures	 of	 intensive	
ovarian	 hyperstimulation,	 such	 as	 supraphysiological	 E2	 levels	 on	
ovulation	 trigger	 day7,20	 and	 a	 high	number	of	 oocytes	 retrieved,6 
have	been	identified	previously	as	independent	risk	factors	for	lower	











1582  |     KOHIL SCHWARTZ eT AL.
birthweight	in	IVF	therapy.	Supraphysiological	E2	levels	are	also	as‐
sociated	with	 a	 higher	 risk	 of	 preeclampsia	 (18).	Our	 results	 even	
suggest	that	the	effect	of	E2	level	on	ovulation	trigger	day	outweighs	
the	choice	of	stimulation	scheme	and	the	amount	of	gonadotropins	




























extra	 villous	 trophoblast	 vascular	 endothelial	 growth	 factor	 and	
hinder	 uterine	 spiral	 artery	 invasion	 into	 the	 placenta.21	 A	 supra‐
physiological	 E2	 environment,	 such	 as	 in	 gonadotropin‐stimulated	
cycles,	may	result	in	an	edematous	endometrium	impairing	tropho‐
blast	differentiation	and	abnormal	placentation,	compared	with	the	







disease,	 hypertension	 and	 diabetes;	 this	 is	 known	 as	 the	 “Barker's	
hypothesis”	 or	 the	 “developmental	 origins	 of	 health	 and	 disease	
theory”.23
IVF	offspring	have	not	yet	reached	late	adult	life.	Multiple	stud‐
ies	 suggest	 that	 c‐IVF	children,	 especially	with	 an	associated	 fetal	
growth	 restriction,24	 may	 face	 health	 issues	 later	 in	 life,	 such	 as	





The	extent	 to	which	 gonadotropin	 stimulation	 is	 associated	
with	 LBW	 and	 SGA,	 and	 consequently	 their	 possible	 negative	
health	 conditions,	 is	 still	 not	 clear.	 However,	 while	 we	 cannot	
alter	 many	 factors	 in	 IVF	 therapy	 to	 achieve	 acceptable	 preg‐
nancy	 outcomes,	 we	 can	 reduce	 the	 use	 of	 gonadotropin	 and	
the	dosage	when	it	is	used.	Furthermore,	the	risk	of	SGA	can	be	
reduced	 by	 frozen	 embryo	 transfer	 cycles,	 but	 there	 instead	 a	
higher	risk	of	 large‐for‐gestational‐age	 (LGA),27	and	preeclamp‐
sia28	 has	 been	 described	 recently.	 In	 NC‐IVF,	 the	 serum	 E2	
milieu	 remains	 within	 physiologic	 limits,17,29 whereas gonado‐
tropin	stimulation	in	c‐IVF	alters	 it.	NC‐IVF	as	well	as	 low‐dose	













much	 known	 about	 perinatal	 outcome	 including	 the	 effect	 on	
LBW	and	SGA.
5  | CONCLUSION
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